A new medicine for acute disseminated encephalomyelitis (ADEM)
Official title: Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through IND enabling studies and translational mouse models for acute disseminated encephalomyelitis (ADEM)
Funded at Trethera Corporation · NIH-11129843 · Data updated 2026-11-12
This project is developing a new medicine to help children and adults with acute disseminated encephalomyelitis, a serious autoimmune disease affecting the brain and spinal cord.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Trethera Corporation NIH-funded |
| Lab location | 1 site (Sherman Oaks, United States) |
| Project start | July 2, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $1,000,000 |
| NIH project number | 5R44AI186534-02 |
| Project ID | NIH-11129843 on NIH RePORTER |
Who could benefit from this research
✓Could help
This research is focused on developing a treatment for patients, especially children, who have acute disseminated encephalomyelitis (ADEM).
✕Less likely to help
Patients without acute disseminated encephalomyelitis (ADEM) would not directly benefit from this specific treatment.
What this research studies
Acute disseminated encephalomyelitis (ADEM) is an autoimmune condition that mostly affects children, causing symptoms like fever, balance problems, and even coma. Current treatments, like corticosteroids, can have significant side effects and don't always fully help patients recover. Our company is working on a new drug called TRE-515, which aims to specifically stop the overactive immune cells that cause ADEM. We hope this new approach will offer a more effective treatment with fewer side effects for those living with ADEM.
Why it matters
Potential benefit: If successful, this new medicine could provide a more effective and safer treatment option for patients with ADEM, potentially reducing long-term disability and improving recovery.
How similar studies have gone: Preliminary studies in mouse models of ADEM have shown promising results, indicating the drug can block disease symptoms and reduce immune cell activity.
Where this research is happening
-
Trethera Corporation
Sherman Oaks, United States Active
Researchers
- Principal investigator: Schultz, Kenneth — Trethera Corporation
- Study coordinator: Schultz, Kenneth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.